A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg

NCT06965998

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Ottawa Hospital Research Institute
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (4)

- Adult patients age e 18 years old.
- Objectively confirmed diagnosis within 14 days of an acute symptomatic SVT of the lower extremities by standardized CUS, where SVT is defined as incompressibility of a venous segment located along the course of a known superficial vein.
- Anticoagulation for SVT is warranted per clinicians.
- Able and willing to provide written informed consent.

Exclusion (16)

- Other indication(s) for therapeutic or prophylactic dose anticoagulation (e.g. atrial fibrillation, mechanical valve, etc.).
- History of PE or DVT within 6 months (180 days) of screening.
- \>5 days of any anticoagulants for the index SVT.
- Requires use of aspirin \>100mg daily or other antiplatelet agents.
- Patients receiving concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-gp (e.g. cobicistat, ketoconazole, itraconazole, posaconazole, ritanovir, etc.).

... and 11 more (see full listing online)

Locations (2 total)

The Ottawa Hospital, Ottawa, Ontario, Canada
Hopital Montfort, Ottawa, Ontario, Canada